El-Shater Bosaily, A
Valerio, M
Hu, Y
Freeman, A
Jameson, C
Brown, L
Kaplan, R
Hindley, R G
Barratt, D
Emberton, M
Ahmed, H U
Article History
Received: 25 October 2015
Revised: 30 December 2015
Accepted: 26 January 2016
First Online: 12 July 2016
Competing interests
: ME and HUA would like to acknowledge funding from the Medical Research Council (UK), the Pelican Cancer Foundation charity, Prostate Cancer UK, St Peters Trust charity, Prostate Cancer Research Centre, the Wellcome Trust, National Institute of Health Research-Health Technology Assessment programme, and the US National Institute of Health-National Cancer Institute. ME receives funding in part from the UK National Institute of Health Research UCLH/UCL Comprehensive Biomedical Research Centre. ME and HUA receive funding from USHIFU, GSK, AngioDynamics and Advanced Medical Diagnostics for clinical trials. ME is a paid consultant to AngioDynamics, Steba Biotech and SonaCare Medical (previously called USHIFU). Both have previously received consultancy payments from Oncura/GE Healthcare and Steba Biotech. None of these sources had any input whatsoever into this article. YH is funded by the Health Technology Innovation Fund, a parallel funding partnership between the Wellcome Trust and the Department of Health. RGH has previously received payments from SonaCare Medical (formerly USHIFU) and Nuada Medical for consultancy work. The remaining authors declare no conflicts of interest.